Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Oncology
Oncology · The big question

Triple-Drug Combo Eradicates Leukemia Stem Cells in Early Tests

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.

PubMed2 min readAI-assisted summary
Editorial illustration for P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.
Editorial illustration

Summary

Acute myeloid leukemia, or AML, is a fast-growing and deadly blood cancer that remains notoriously difficult to cure. Traditional chemotherapy is harsh on the body and currently offers patients a five-year survival rate of just 25 percent at best. While doctors have some targeted drugs available to help extend life, a truly curative treatment has remained out of reach. Now, researchers have identified a promising new approach that combines three different medications to strike at the root of the disease.

The experimental treatment targets a specific genetic subtype of the disease known as DNMT3A/FLT3-mutant AML. Scientists combined two existing targeted drugs, venetoclax and gilteritinib, with a newer medication called inobrodib. Together, this triple-drug combination essentially starved the cancer. By blocking the critical factors that the cancer needs to survive and multiply, the treatment completely shut down the leukemia growth process. In fact, the combination virtually eliminated the leukemia stem cells, which act as the hidden seeds that allow the cancer to persist and return.

While these results are highly encouraging, it is important to note that the research is still in its early stages. The dramatic elimination of leukemia stem cells was demonstrated in an aggressive preclinical laboratory model, rather than in human patients. Before this triple combination therapy can become an approved option in cancer clinics, it must undergo rigorous human clinical trials to confirm both its safety and its true clinical utility.

Why it matters.

The broader significance of this research lies in its potential to radically improve a very grim prognosis. With current standard therapies offering at best a 25 percent chance of surviving five years, the vast majority of AML patients face a heartbreaking lack of options. The persistent challenge in treating blood cancers is that a few surviving leukemia stem cells can cause the disease to relapse even after successful chemotherapy. By completely wiping out these foundational cancer cells, this new combination therapy aims directly at the root cause of relapse.

If this triplet combination proves successful in human trials, it could mark a major shift in how oncologists approach aggressive blood cancers. Moving away from highly toxic standard chemotherapy toward a more precise, multi-drug attack could finally offer patients with this specific genetic mutation a genuine chance at a cure, rather than just a brief extension of life.

From the source

The story in numbers.

Maximum 5-year survival rate with current cytotoxic chemotherapy
25%
Targeted inhibitors in the proposed combination therapy (inobrodib, venetoclax, gilteritinib)
3
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Oncology

Targeted Drug Spares Lymphoma Patients from Stem Cell Transplants

Mantle cell lymphoma is a challenging type of blood cancer. For years, the standard treatment for younger, relatively fit patients has been a heavy dose of chemotherapy followed by an autologous stem cell transplant. This transplant process involves collecting a patient's own healthy stem cells, delivering high-dose chemotherapy to wipe out the cancer, and then returning the healthy cells to help the body recover. It is an intense procedure that can be incredibly hard on the body. A recent major clinical trial followed 870 patients across Europe and Israel for over four years to see if adding a targeted daily pill called ibrutinib could improve outcomes. Researchers split the patients into three groups to test different combinations of standard chemotherapy, ibrutinib, and stem cell transplants. They found that adding ibrutinib significantly boosted both how long patients lived overall and how long they lived without their cancer returning or worsening. The most welcome discovery was that the grueling stem cell transplant may no longer be necessary. The group that received chemotherapy and ibrutinib but skipped the transplant did just as well as the group that received all three. Adding the transplant to the ibrutinib regimen provided no extra survival benefit but significantly increased the risk of severe side effects, like dangerous drops in healthy blood cells. It is worth noting that this study only looked at untreated patients aged 18 to 65, so the findings might not apply to older or less fit individuals.

PubMed2 min read
Oncology

Colorectal Cancer Prepares to Spread Earlier Than We Thought

For anyone diagnosed with cancer, the most dangerous moment is when the disease begins to spread to new areas of the body, a process known as metastasis. Scientists have long wondered exactly when and how a localized tumor gains the ability to travel. In a new study looking at colorectal cancer, researchers made a surprising discovery. They found that tumors actually develop the necessary tools to spread much earlier than previously believed. By studying patient samples and miniature lab-grown tumors called organoids, the research team looked at how tumor cells behave at a microscopic level. They discovered that many early-stage tumors adopt a highly flexible condition called an oncofetal state. Normally, this shapeshifting ability is only seen in advanced, late-stage cancers. But the researchers found that these flexible cancer cells were already gathering at the edges of early tumors. There, they mingle with normal connective tissue cells known as fibroblasts, which actively encourage the cancer cells to become even more adaptable and ready to move. However, simply having these flexible cells is not enough to guarantee the cancer will spread, since not all early-stage tumors actually go on to metastasize. The researchers investigated what pushes the tumor over the edge. They ruled out new genetic mutations as the trigger. Instead, their findings suggest that a cancer cell's ability to hide from the immune system might be the final key to unlocking its deadly spread.

Nature Genetics2 min read
Oncology

New nanoparticle tech breaks down tumor shields to boost immunity

Tumors have a sneaky way of hiding from the body's immune system. They wrap themselves in a dense, sugary protective coating known as the glycocalyx. This shield is packed with mucins, which are thick proteins that physically block immune cells and modern cancer treatments from reaching the target. While scientists have discovered a bacterial enzyme called StcE that can chew through this sticky barrier, using it as a drug has been difficult. Injecting the free enzyme directly into the body causes unwanted toxic side effects and triggers severe immune reactions. To solve this problem, researchers engineered a clever delivery system using cell membrane fusion nanovesicles, which are essentially microscopic bubbles made from natural cell materials. They equipped these tiny delivery vehicles with both the barrier-breaking StcE enzyme and specialized targeting molecules called CD47 nanobodies. These nanobodies act like a homing device that seeks out cancer cells. By using this biomimetic delivery platform, the enzyme successfully digests the protective sugary shield precisely at the tumor site, avoiding the widespread toxicity and safety issues of the free enzyme. With the barrier cleared away, the immune system gets a much clearer shot at the tumor. The researchers found that removing the mucin shield allowed the nanobodies to bind tightly to the cancer cells, sounding the alarm for the body's natural defenses. The treatment successfully suppressed tumor growth and stopped the cancer from spreading by radically remodeling the environment around the tumor, bringing in a flood of protective immune cells.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗